FDA reports rare cases of worsening liver function or liver failure in patients with chronic hepatitis C virus (HCV) who had moderate-to-severe liver impairment and were treated with Mavyret, Zepatier, or Vosevi, despite these drugs being contraindicated in this group of patients.
Among patients with hepatitis C virus (HCV) infection and complete response to hepatocellular carcinoma (HCC) treatment, direct-acting antiviral (DAA) therapy is associated with a significant reduction in the risk for death.
Researchers conducted a retrospective cohort study to determine the clinical features of pediatric patients with PSC in a Japanese cohort to evaluate long-term outcomes. They discovered that primary sclerosing cholangitis (PSC)-autoimmune hepatitis overlap is the primary phenotype linked to poor long-term outcomes.
In Spain, researchers found data from a real-world cohort that showed that retreatment and a sustained viral response, depending upon treatment nonresponse and genotype, can be achieved with certain combinations of direct-acting antivirals.
The researchers found that lipophilic statin users had a significantly lower 10-year HCC risk compared with matched nonusers (8.1 versus 3.3 percent; absolute risk difference [RD], −4.8 percent; adjusted subdistribution hazard ratio [aHR], 0.56; 95 percent confidence interval [CI], 0.41 to 0.79), while hydrophilic statin users did not have a lower risk (8.0 versus 6.8 percent; RD, −1.2 percent; aHR, 0.95; 95 percent CI, 0.86 to 1.08).
Researchers in Australia found that treatment with direct acting antivirals for hepatitis C in the primary care setting is effective in treatment uptake in people who inject drugs, compared with referrals to hospital-based services.